Resistencia antimicrobiana

Referencias

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat -report-2013/. Accessed January 12, 2016.

2. President’s Council of Advisors on Science and Technology. Report to the President on combating Review of Antimicrobial Resistance Special Communication Clinical Review& Education jama.com (Reprinted) JAMA September 20, 2016 Volume 316, Number 11 1201

3. Gelband H, Miller-Petrie M, Pant S, et al. State of theWorld's Antibiotics, 2015.Washington, DC: Center for Disease Dynamics, Economics, and Policy; 2015. http://cddep.org/publications/state _worlds_antibiotics_2015#sthash.l18BFUu2.dpbs. Accessed January 6, 2016.

4. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046-5054.

5. Liu YY,Wang Y,Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism mcr-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-168.

6. Pray L. Antibiotic resistance, mutation rates and MRSA. Nature Educ. 2008;1(1):30.

7. D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature. 2011;477(7365):457-461.

8. Bhullar K,Waglechner N, Pawlowski A, et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One. 2012;7(4):e34953.

9. Hall BG, Salipante SJ, BarlowM. Independent origins of subgroup Bl + B2 and subgroup B3 metallo-β-lactamases. J Mol Evol. 2004;59(1):133-141.

10. Van Boeckel TP, Brower C, GilbertM, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112(18):5649-5654.

11. US Food and Drug Administration. 2014 Summary report on antimicrobials sold or distributed for use in food-producing animals. http://www.fda.gov/downloads/ForIndustry /UserFees/AnimalDrugUserFeeActADUFA /UCM476258.pdf. Published December 2015. Accessed January 12, 2016.

12. Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24(4):718-733.

13. Chantziaras I, Boyen F, Callens B, Dewulf J. Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. J Antimicrob Chemother. 2014;69(3):827-834.

14. Price LB, Stegger M, Hasman H, et al. Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock. MBio. 2012;3(1):e00305-11.

15. US Food and Drug Administration. Final Rule: Antimicrobial Animal Drug Sales and Distribution Reporting. https://federalregister.gov/articles/2016 /05/11/2016-11082/antimicrobial-animal-drug -sales-and-distribution-reporting. Published 2016. Accessed June 20, 2016.

16. Schmieder R, Edwards R. Insights into antibiotic resistance through metagenomic approaches. Future Microbiol. 2012;7(1):73-89.

17. Ayliffe GA. Cephalosporinase and penicillinase activity of gram-negative bacteria. J Gen Microbiol. 1965;40(1):119-126.

18. Lee EH, Nicolas MH, Kitzis MD, Pialoux G, Collatz E, Gutmann L. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother.1991;35(6):1093-1098.

19. US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Published 2016. Accessed June 21, 2016.

20. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62 (10):e51-e77.

21. Joint Commission. Approved: new antimicrobial stewardship standard. https://www .jointcommission.org/new_antimicrobial _stewardship_standard/. Published July 19, 2016. Accessed August 24, 2016.

22. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Danziger LH. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009. J Antimicrob Chemother. 2013;68(3): 715-718.

23. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 2016;315(17):1864-1873.

24. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN,Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011;11(9):692-701.

25. Centers for Disease Control and Prevention. Get Smart About AntibioticsWeek. https://www.cdc.gov/getsmart/week/. Published February 2016. Accessed August 24, 2016.

26. Travasso C. India draws a red line under antibiotic misuse. BMJ. 2016;352:i1202.

27. Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA. 2016;315(6):562-570.

28. Gerber JS, Prasad PA, Fiks AG, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. JAMA. 2013;309(22):2345-2352.

29. Boucher HW, Talbot GH, Benjamin DK Jr, et al; Infectious Diseases Society of America. 10 x ’20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56(12):1685-1694.

30. US Food and Drug Administration. New drugs at FDA. http://www.fda.gov/Drugs /DevelopmentApprovalProcess/DrugInnovation /ucm483775.htm. Accessed August 24, 2016.

31. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the US, 1980-2009. J Law Med Ethics. 2013;41(3):688-696.

32. Theuretzbacher U. Recent FDA antibiotic approvals: good news and bad news. Center for Disease Dynamics, Economics, and Policy website. http://cddep.org/blog/posts/recent_fda_antibiotic_approvals_good_news_and_bad_news#sthash.GFOk734M.dpbs. Published March 12, 2015. Accessed June 21, 2016.

33. The Pew Charitable Trusts. Antibiotics currently in clinical development. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development. Published 2015. Accessed June 16, 2016.

34. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387(10014):168-175.

35. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother. 2007;51(8):3026-3029.

36. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA. 2015;314(14):1479-1487.

37. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54-60.

38. Mathers AJ, Cox HL, Kitchel B, et al. Molecular dissection of an outbreak of carbapenem-resistant enterobacteriaceae reveals intergenus KPC carbapenemase transmission through a promiscuous plasmid. MBio. 2011;2(6):e00204-e00211.

39. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma. 2013; 54(4):799-806.

40. Snitkin ES, Zelazny AM, Thomas PJ, et al; NISC Comparative Sequencing Program Group. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med. 2012;4(148):148ra116.

41. Dortet L, Poirel L, Nordmann P.Worldwide dissemination of the NDM-type carbapenemases in gram-negative bacteria. Biomed Res Int. doi:10.1155/2014/249856

42. Berrazeg M, Diene S, Medjahed L, et al. New Delhi metallo-β-lactamase around the world: an eReview using Google Maps. Euro Surveill. 2014;19(20):20809.

43. Biedenbach D, Bouchillon S, Hackel M, et al. Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012. Antimicrob Agents Chemother. 2015;59(2):826-830.

44. Walsh TR,Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11(5):355-362.

45. Datta S, Roy S, Chatterjee S, et al. A five-year experience of carbapenem resistance in Enterobacteriaceae causing neonatal septicaemia: predominance of NDM-1. PLoS One. 2014;9(11):e112101.

46. Kumarasamy KK, Toleman MA,Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597-602.

47. Lyman M,Walters M, Lonsway D, Rasheed K, Limbago B, Kallen A. Notes from the field: carbapenem-resistant Enterobacteriaceae producing OXA-48-like carbapenemases—United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2015;64(47):1315-1316.

48. Khatri A, Naeger Murphy N, Wiest P, et al. Community-acquired pyelonephritis in pregnancy caused by KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;59(8):4375-4378.

49. Nordmann P, Couard JP, Sansot D, Poirel L.Emergence of an autochthonous and community-acquired NDM-1–producing Klebsiella pneumoniae in Europe. Clin Infect Dis. 2012;54(1):150-151.

50. Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallo-β-lactamase–producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA. 2014;312 (14):1447-1455.

51. Rubin Z. Carbapenem-resistant Klebsiella pneumoniae following ERCP at RRUMC December, 2014 to January, 2015. Paper presented at: Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee; May 14-15, 2015; Silver Spring, MD.

52. Guerra B, Fischer J, Helmuth R. An emerging public health problem: acquired carbapenemaseproducing microorganisms are present in food-producing animals, their environment, companion animals and wild birds. Vet Microbiol.

2014;171(3-4):290-297.

53. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699-1709.

54. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumonia carbapenemase–producing K pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943-950.